Bicycle Therapeutics’ (BCYC) Buy Rating Reiterated at HC Wainwright
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $55.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 143.90% from the company’s previous close. Other research […]
More Stories
Nio Inc – (NYSE:NIO) Given Average Rating of “Hold” by Analysts
Nio Inc – (NYSE:NIO – Get Free Report) has earned a consensus recommendation of “Hold” from the twelve research firms...
Nio Inc – (NYSE:NIO) Given Average Rating of “Hold” by Analysts
Nio Inc – (NYSE:NIO – Get Free Report) has earned a consensus recommendation of “Hold” from the twelve research firms...
UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received an average rating of “Buy” from the six brokerages that...
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Buy” by Analysts
enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has earned an average rating of “Buy” from the eleven research firms...
Newell Brands Inc. (NASDAQ:NWL) Given Average Recommendation of “Hold” by Analysts
Newell Brands Inc. (NASDAQ:NWL – Get Free Report) has received an average rating of “Hold” from the eleven research firms...
CyberArk Software Ltd. (NASDAQ:CYBR) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of CyberArk Software Ltd. (NASDAQ:CYBR – Get Free Report) have received an average rating of “Moderate Buy” from the...